AlloVir (Nasdaq:ALVR) - 주가, 뉴스 및 분석

ALVR 주식 개요

임상 단계의 세포 치료제 회사인 알로비어는 치명적인 바이러스 관련 질병을 예방하고 치료하기 위해 동종 기성 다중 바이러스 특이적 T 세포(VST) 치료제를 연구 및 개발하는 기업입니다. 자세한 내용

ALVR 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

최근 3개월간 주가 변동성

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

+ 1 더 많은 위험

AlloVir, Inc. 경쟁사

Cue Biopharma

NasdaqCM:CUE

US$64.6m

Spero Therapeutics

NasdaqGS:SPRO

US$63.2m

Cellectar Biosciences

NasdaqCM:CLRB

US$64.1m

BioAtla

NasdaqGM:BCAB

US$75.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 AlloVir
과거 주가
현재 주가	US$0.55
52주 최고치	US$2.49
52주 최저치	US$0.52
베타	0.74
11개월 변경	-31.52%
3개월 변경 사항	-29.56%
1년 변경 사항	-64.52%
33년 변화	-96.99%
5년 변화	n/a
IPO 이후 변화	-97.83%

최근 뉴스 및 업데이트

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

주주 수익률

	ALVR	US Biotechs	US 마켓
7D	-3.4%	2.5%	2.2%
1Y	-64.5%	16.1%	31.6%

수익률 대 산업: ALVR 지난 1년 동안 16.1 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ALVR 지난 1년 동안 31.6 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ALVR's price volatile compared to industry and market?
ALVR volatility
ALVR Average Weekly Movement	15.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: ALVR 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ALVR 의 주간 변동성( 16% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2013	8	Diana Brainard	www.allovir.com

임상 단계의 세포 치료제 회사인 Allovir, Inc.는 치명적인 바이러스 관련 질병을 예방하고 치료하기 위한 동종 기성 다중 바이러스 특이적 T 세포(VST) 치료제의 연구 및 개발에 종사하고 있습니다. 이 회사의 주요 제품은 BK 바이러스, 거대세포 바이러스, 아데노 바이러스, 엡스타인-바 바이러스, 인간 헤르페스 바이러스 6 및 JC 바이러스를 치료하는 동종 기성 VST 치료제인 포솔루셀입니다. 전임상 및 임상 개발 제품 후보로는 호흡기 세포융합 바이러스, 인플루엔자, 파라인플루엔자 바이러스, 인간 메타뉴모바이러스 치료를 위한 ALVR106, SARS-CoV-2 및 COVID-19 치료를 위한 ALVR109, B형 간염 치료를 위한 ALVR107, ALVR108 등이 있습니다.

AlloVir, Inc. 기본 사항 요약

AlloVir 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ALVR 기본 통계
시가총액	US$62.92m
수익(TTM)	-US$100.20m
수익(TTM)	n/a

0.0x

P/S 비율

-0.6x

P/E 비율

ALVR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ALVR 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$100.20m
수익	-US$100.20m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.88
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

ALVR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ALVR 주식 개요

위험 분석

AlloVir, Inc. 경쟁사

NasdaqCM:CUE

US$64.6m

NasdaqGS:SPRO

US$63.2m

NasdaqCM:CLRB

US$64.1m

NasdaqGM:BCAB

US$75.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Recent updates

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock